Merck Expects Underlying Operating Expenses To Increase Mid- To High-Single Digits Next Year; For Keytruda Expecting Moderating Growth As We Approach Peak Revenues For Certain Approved Indications; For Keytruda, Expecting German Market To Be Impacted By Policy Dynamics; Expecting Keytruda & Winrevair Benefit To Fully Unwind In Q4; Majority Of Vaccines Benefit, Primarily Gardasil, To Unwind In 2027

뉴스 본문을 불러오고 있어요.

Merck Expects Underlying Operating Expenses To Increase Mid- To High-Single Digits Next Year; For Keytruda Expecting Moderating Growth As We Approach Peak Revenues For Certain Approved Indications; For Keytruda, Expecting German Market To Be Impacted By Policy Dynamics; Expecting Keytruda & Winrevair Benefit To Fully Unwind In Q4; Majority Of Vaccines Benefit, Primarily Gardasil, To Unwind In 2027 | 웨이프 WAPE

기사 요약

관련 종목

댓글 —